Therapeutic methods and compositions
AssigneeInstitut Pasteur
InventorsJacques Theze, Thierry Rose, Florence Bugault
Life of this patent
Estimating the term…
Abstract
Methods for diagnosing or treating immune disorders in a subject are provided. The methods are based on the detection or modulation of Refractory state Inducing Factor (RIF).
Claims16
A method for stimulating an immune response in a subject having a disorder associated with a CD4 T cell immune deficiency, or for treating a disorder associated with a CD4 T cell immune deficiency in a subject, comprising administering to the subject an effective amount of an inhibitor of secreted phospholipase A2 group IB (GIBsPLA2), said GIBsPLA2 inhibitor being:
- a) a polyclonal antibody that binds to GIBsPLA2 or a GIBsPLA2-binding fragment of said polyclonal antibody, said polyclonal antibody or GIBsPLA2-binding fragment thereof inhibiting a GIBsPLA2 enzymatic activity, wherein said GIBsPLA2 is a protein comprising amino acid residues 23-148 of SEQ ID NO:
- 2 or a naturally-occurring variant thereof;
- or
- b) a soluble GIBsPLA2-binding protein comprising a sequence selected from any one of SEQ ID NOs:
- 22-31.
A method for stimulating an immune response in a subject having a disorder associated with a CD4 T cell immune deficiency, or for treating a disorder associated with a CD4 T cell immune deficiency in a subject, comprising administering to the subject an effective amount of an inhibitor of secreted phospholipase A2 group IB (GIBsPLA2), said GIBsPLA2 inhibitor being a polyclonal antibody that binds to GIBsPLA2 or a GIBsPLA2-binding fragment thereof, said polyclonal GIBsPLA2-binding antibody or GIBsPLA2-binding fragment inhibiting a GIBsPLA2 enzymatic activity, wherein said GIBsPLA2 is a protein comprising amino acid residues 23-148 of SEQ ID NO:
- 2 or a naturally-occurring variant thereof.
A method for stimulating an immune response in a subject having a disorder associated with a CD4 T cell immune deficiency, or for treating a disorder associated with a CD4 T cell immune deficiency in a subject, comprising administering to the subject an effective amount of an inhibitor of secreted phospholipase A2 group IB (GIBsPLA2), said GIBsPLA2 inhibitor being a soluble GIBsPLA2 binding protein comprising a sequence selected from any one of SEQ ID NOs:
- 22-31.
Dependencies are inferred from the claim text.